Literature DB >> 29424889

LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290.

X-J Lai1, H-F Cheng.   

Abstract

OBJECTIVE: Ovarian cancer is one of the leading causes of cancer-related death in women, but treatment remained unsatisfactory. Studies have shown that lncRNA colon cancer-associated transcript 1 (CCAT1) plays an important regulatory role in different cancers, but its role in ovarian cancer remained largely unclear. PATIENTS AND METHODS: Quantitative Real-time polymerase chain reaction (qRT-PCR) was applied to detect the expression of lncRNA CCAT1 in ovarian cancer and adjacent tissue, and analysis was applied to explore the relationship between expression and clinical characteristic. After lncRNA CCAT1 suppression, Cell Counting Kit-8 (CCK8) and wound-healing assay were used to detect the proliferation and metastasis ability of ovarian cancer, respectively.
RESULTS: qRT-PCR showed that lncRNA CCAT1 was highly expressed in ovarian cancer tissue, compared with adjacent tissue. Moreover, we found that the expression of lncRNA CCAT1 was closely related to prognosis, tumor size, and lymph node metastasis. We also found that lncRNA CCAT1 could sponge miR-1290 in ovarian cancer.
CONCLUSIONS: In this study, we found that lncRNA CCAT1 could sponge miR-1290 in ovarian cancer, and was closely related to prognosis, proliferation, and metastasis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29424889     DOI: 10.26355/eurrev_201801_14175

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  15 in total

1.  Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis.

Authors:  Huiying Xu; Lingyan Wang; Xiuli Jiang
Journal:  Mol Cell Biochem       Date:  2020-11-10       Impact factor: 3.396

2.  MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer.

Authors:  Chuang Yang; Minghua Wang; Junde Zhou; Qiang Chi
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

3.  Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.

Authors:  De-Ying Wang; Na Li; Yu-Lan Cui
Journal:  Cancer Res Treat       Date:  2020-03-03       Impact factor: 4.679

4.  CCAT1 promotes triple-negative breast cancer progression by suppressing miR-218/ZFX signaling.

Authors:  Chunyong Han; Xuebiao Li; Qian Fan; Guangshu Liu; Jian Yin
Journal:  Aging (Albany NY)       Date:  2019-07-16       Impact factor: 5.682

Review 5.  Oncogenic seRNA functional activation: a novel mechanism of tumorigenesis.

Authors:  Yuan Tan; Yuejin Li; Faqing Tang
Journal:  Mol Cancer       Date:  2020-04-11       Impact factor: 27.401

6.  Potential diagnostic and prognostic value and regulatory relationship of long noncoding RNA CCAT1 and miR-130a-3p in clear cell renal cell carcinoma.

Authors:  Jingjing Jing; Xu Zhao; Jiannan Wang; Tan Li
Journal:  Cancer Cell Int       Date:  2021-01-22       Impact factor: 5.722

Review 7.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

8.  lncRNA FLVCR1‑AS1 drives colorectal cancer progression via modulation of the miR‑381/RAP2A axis.

Authors:  Yi Han; Xiaoyan Wang; Enqiang Mao; Boyong Shen; Liang Huang
Journal:  Mol Med Rep       Date:  2020-12-14       Impact factor: 2.952

9.  Long noncoding RNA EZR-AS1 promotes tumor growth and metastasis by modulating Wnt/β-catenin pathway in breast cancer.

Authors:  Yu Bai; Xian Zhou; Luo Huang; Yue Wan; Xiaoyu Li; Ying Wang
Journal:  Exp Ther Med       Date:  2018-07-18       Impact factor: 2.447

10.  Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.

Authors:  Xiaohui Li; Xingtao Han; Pengtao Wei; Jinhui Yang; Jiantao Sun
Journal:  Cancer Biol Ther       Date:  2020-02-23       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.